Article
Radiology, Nuclear Medicine & Medical Imaging
Yining Wang, Zijun Chen, Yinjie Zhu, Haitao Zhao, Lianghua Li, Gang Huang, Wei Xue, Ruohua Chen, Jianjun Liu
Summary: The purpose of this study was to assess whether total-body [(68) Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with conventional [(68) Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer. The results showed that total-body [(68) Ga]Ga-PSMA-11 PET/CT had better objective evaluation in terms of background noise, lesion prominence, liver SD, SNR, and lesion SUVmax compared with conventional [(68) Ga]Ga-PSMA-11 PET/CT. Overall, total-body [(68) Ga]Ga-PSMA-11 PET/CT had a significantly higher detection rate for biochemical recurrent prostate cancer compared to conventional [(68) Ga]Ga-PSMA-11 PET/CT. Rating: 9/10.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiaomei Gao, Yongxiang Tang, Minfeng Chen, Jian Li, Hongling Yin, Yu Gan, Xiongbin Zu, Yi Cai, Shuo Hu
Summary: This study compared [Ga-68]Ga-RM26 PET/CT and [Ga-68]Ga-PSMA-617 PET/CT for diagnosing prostate cancer, and found that [Ga-68]Ga-PSMA-617 PET/CT had superior accuracy in detecting clinically significant PCa, while [Ga-68]Ga-RM26 PET/CT showed an advantage for imaging low-risk PCa.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Review
Oncology
Ruizhe Huang, Yizhen Li, Haowen Wu, Boyi Liu, Xuanjun Zhang, Zhongxi Zhang
Summary: The aim of this study was to compare the diagnostic efficacy of Ga-68-PSMA-11 PET/CT and Ga-68-PSMA-11 PET/MRI in patients with biochemically recurrent prostate cancer. A meta-analysis and systematic review were conducted, analyzing 37 studies involving 8409 patients. The results showed that Ga-68-PSMA-11 PET/CT and Ga-68-PSMA-11 PET/MRI had similar detection rates for biochemically recurrent prostate cancer. However, larger prospective studies are needed to confirm these findings.
FRONTIERS IN ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jun Wen, Yinjie Zhu, Lianghua Li, Jianjun Liu, Yumei Chen, Ruohua Chen
Summary: Dynamic total-body PET imaging in patients with prostate cancer showed that 6 minutes post-injection was the optimal time for imaging, avoiding interference from bladder activity and detecting lesions with relatively low PSMA uptake. Additionally, imaging at 35-59 minutes post-injection could also yield similar results to imaging at 60 minutes post-injection.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yuheng Liu, Lianghua Li, Yanyu Qin, Zijun Chen, Haitao Zhao, Xinlu Wang, Ruohua Chen
Summary: The objective of this study was to compare the diagnostic performance and image quality of total-body PET/CT imaging using half-dose of [(68) Ga]Ga-PSMA radiotracer to conventional PET/CT imaging using full dose of [(68) Ga]Ga-PSMA. The results showed that total-body PET/CT with half-dose of [(68) Ga]Ga-PSMA yielded comparable image quality and diagnostic performance to conventional PET/CT, while reducing radiation exposure for the subjects.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Wenxiao Yu, Ming Zhao, Yingjun Deng, Shengjing Liu, Guanchao Du, Bin Yan, Ziwei Zhao, Ning Sun, Jun Guo
Summary: This study compared the diagnostic value of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and Ga-68-PSMA PET/CT in prostate cancer. The results showed that both (18) F-PSMA-1007 PET/CT and Ga-68 PSMA PET/CT demonstrated higher diagnostic efficacy compared to (18) F-FDG PET/CT.
Article
Medicine, General & Internal
Manuela A. Hoffmann, Jonas Mueller-Huebenthal, Florian Rosar, Nicolas Fischer, Finn Edler von Eyben, Hans-Georg Buchholz, Helmut J. Wieler, Mathias Schreckenberger
Summary: This study compared the performance of [F-18]PSMA-1007 and [Ga-68]Ga-PSMA-11 positron emission tomography/computed tomography in the initial staging of prostate cancer patients. The results showed that both methods were able to detect PSMA-avid lesions with high concordance to histopathologically proven cancer. There was no superior advantage of either method in diagnosing prostate cancer.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wojciech Cytawa, Stefan Kircher, Hubert Kuebler, Rudolf A. Werner, Simon Weber, Philipp Hartrampf, Tomasz Bandurski, Piotr Lass, Wojciech Polom, Marcin Matuszewski, Hans-Juergen Wester, Constantin Lapa, Andreas Rosenwald, Anna Katharina Seitz, Andreas K. Buck
Summary: The purpose of this study was to validate the expression of primary tumor PSMA in prostate cancer patients using [Ga-68]Ga-PSMA PET/CT imaging. The results showed that among PSMA-positive patients, about one-third had lymph node metastases, which were associated with PSMA expression and tumor volume. In contrast, only 1 out of 7 PET-negative patients had lymph node involvement. These results suggest that PSMA-positive prostate cancer may have a higher risk of aggressiveness and distant metastasis.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
David A. Pattison, Maciej Debowski, Brook Gulhane, Evyn G. Arnfield, Anita M. Pelecanos, Peter L. Garcia, Melissa J. Latter, Charles Y. Lin, Matthew J. Roberts, Stuart C. Ramsay, Paul A. Thomas
Summary: This study aimed to compare the concordance of [F-18]PSMA-1007 and [(68)Ga]Ga-PSMA-11 in TNM diagnosis and tracer uptake. The results showed differences in tracer uptake in most physiological sites, but high consistency in overall AJCC prognostic stage.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ruohua Chen, Yee Ling Ng, Xinlan Yang, Yinjie Zhu, Lianghua Li, Haitao Zhao, Yun Zhou, Gang Huang, Jianjun Liu
Summary: Total-body parametric imaging of [(68) Ga]Ga-PSMA-11 improved lesion contrast and detectability compared to SUV images, which may serve as an imaging biomarker and theranostic tool for precise diagnosis and treatment evaluation in prostate cancer patients.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Guochang Wang, Linlin Li, Jie Zang, Haiyan Hong, Lin Zhu, Hank F. Kung, Zhaohui Zhu
Summary: This study compared the diagnostic performance of Ga-68-P16-093 and Ga-68-PSMA-617 PET/CT in primary prostate cancer patients. The results showed that Ga-68-P16-093 PET/CT detected more positive tumors and had higher tumor uptake and better tumor detection capability than Ga-68-PSMA-617 PET/CT.
CLINICAL NUCLEAR MEDICINE
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Jiayu Cai, Weizhi Xu, Tinghua Meng, YiZhen Pang, Haojun Chen
Summary: Mixed neuroendocrine carcinoma-acinar carcinoma is a rare type of neuroendocrine prostate cancer and has rarely been reported in de novo cases. In this case, we present the PET/CT findings of Ga-68-PSMA, Ga-68-FAPI, and F-18-FDG in the de novo form of mixed large-cell neuroendocrine carcinoma-acinar adenocarcinoma of the prostate. Different levels of radiotracer uptake were observed in metastatic sites on Ga-68-PSMA, Ga-68-FAPI, and F-18-FDG PET/CT. This case demonstrates the potential use of a multitracer PET/CT strategy for noninvasive detection of intermetastatic heterogeneity in metastatic neuroendocrine prostate cancer.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kaan Akcay, Ali Kibar, Onur Erdem Sahin, Muhammet Demirbilek, Gamze Beydagi, Sertac Asa, Fuad Aghazada, Turkay Toklu, Nalan Alan Selcuk, Bulent Onal, Levent Kabasakal
Summary: The study retrospectively reviewed 147 patient records and found that [(68) Ga]Ga-PSMA-11 PET/CT imaging has potential value in diagnosing clinically significant prostate cancer. PRIMARY scoring was more reliable than PIRADS scoring in diagnosing significant prostate cancer.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Venkata Subramanian Krishnaraju, Rajender Kumar, Bhagwant Rai Mittal, Vishal Sharma, Harjeet Singh, Ritambhra Nada, Amanjit Bal, Manish Rohilla, Harmandeep Singh, Surinder S. Rana
Summary: The study aimed to differentiate malignant and benign pancreatic lesions by evaluating PSMA expression and comparing Ga-68 PSMA-PET/CT and F-18 FDG-PET/CT. Ga-68 PSMA-PET/CT showed higher specificity and accuracy in pre-operatively diagnosing primary pancreatic malignancy compared to FDG-PET/CT.
EUROPEAN RADIOLOGY
(2021)
Article
Oncology
Daniel Groener, Jennifer Wichert, Magdalena Adams, Nicolai Mader, Konrad Klimek, Christina Nguyen Ngoc, Justus Baumgarten, Christian Happel, Philipp Mandel, Felix K. H. Chun, Nikolaos Tselis, Frank Gruenwald, Amir Sabet
Summary: This study aims to assess the change in uptake to reference organs, including the liver, parotid, and salivary glands after radioligand therapy (RLT) with [Lu-177]Lu-PSMA-617 in relation to pretreatment imaging metrics. The results showed that RLT has a significant impact on salivary gland uptake, while the changes in liver uptake are burden-dependent.
Article
Urology & Nephrology
Thijs H. Huits, Henk B. Luiting, Henk G. van der Poel, Rohan Nandurkar, Maarten Donswijk, Eva Schaake, Wouter Vogel, Monique J. Roobol, Esther Wit, Phillip Stricker, Louise Emmett, Pim J. van Leeuwen
Article
Oncology
Lodewijka H. J. Holtkamp, Annette H. Chakera, Sebastian Fung, Jonathan R. Stretch, Robyn P. M. Saw, Kenneth Lee, Sydney Ch'ng, Maria Gonzalez, John F. Thompson, Louise Emmett, Omgo E. Nieweg
Article
Surgery
Jonathan Lee, Louise Emmett, Reuben Tang, Bao Ho, Peter Earls, Tim Matthews, Richard Gallagher
ANZ JOURNAL OF SURGERY
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Matthew J. Roberts, Andrew Morton, Peter Donato, Samuel Kyle, David A. Pattison, Paul Thomas, Geoff Coughlin, Rachel Esler, Nigel Dunglison, Robert A. Gardiner, Suhail A. Doi, Louise Emmett, John Yaxley
Summary: Intraprostatic (68)Ga-PSMA-11 intensity is prognostic and may be a valuable new biomarker in localised prostate cancer, especially in men with biopsy-proven Gleason 3 + 4 disease considering an initial approach of active surveillance or focal therapy.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wolfgang P. Fendler, Jeremie Calais, Matthias Eiber, Jeffrey P. Simko, John Kurhanewicz, Romelyn Delos Santos, Felix Y. Feng, Robert E. Reiter, Matthew B. Rettig, Nicholas G. Nickols, Amar U. Kishan, Roger Slavik, Peter R. Carroll, Courtney Lawhn-Heath, Ken Herrmann, Johannes Czernin, Thomas A. Hope
Summary: This study highlights the potential pitfalls of [Ga-68]Ga-PSMA-11 PET interpretation in detecting biochemically recurrent prostate cancer, with false positive interpretations mainly attributed to post-radiotherapy prostate uptake and false negative interpretations often due to small metastases.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Correction
Radiology, Nuclear Medicine & Medical Imaging
Matthew J. Roberts, Andrew Morton, Peter Donato, Samuel Kyle, David A. Pattison, Paul Thomas, Geoff Coughlin, Rachel Esler, Nigel Dunglison, Robert A. Gardiner, Suhail A. Doi, Louise Emmett, John Yaxley
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Oncology
Robin M. Turner, Mbathio Dieng, Nikita Khanna, Mai Nguyen, Jiaxu Zeng, Amanda A. G. Nijhuis, Omgo E. Nieweg, Andrew J. Einstein, Louise Emmett, Sarah J. Lord, Alexander M. Menzies, John F. Thompson, Robyn P. M. Saw, Rachael L. Morton
Summary: Regular 6- or 12-monthly surveillance imaging using CT or PET/CT has reasonable and consistent sensitivity and specificity over 5-year follow-up for resected stage IIIA-D melanoma patients, providing useful data for discussing the risks and benefits of long-term follow-up.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Urology & Nephrology
Nattakorn Dhiantravan, Louise Emmett, Anthony M. Joshua, David A. Pattison, Roslyn J. Francis, Scott Williams, Shahneen Sandhu, Ian D. Davis, Ian Vela, Nitika Neha, Mathias Bressel, Declan G. Murphy, Michael S. Hofman, Arun A. Azad
Summary: The study aims to evaluate the activity and safety of Lu-177-PSMA-617 in men with de novo metastatic hormone-naive prostate cancer.
Article
Radiology, Nuclear Medicine & Medical Imaging
Francesco Ceci, Daniela E. Oprea-Lager, Louise Emmett, Judit A. Adam, Jamshed Bomanji, Johannes Czernin, Matthias Eiber, Uwe Haberkorn, Michael S. Hofman, Thomas A. Hope, Rakesh Kumar, Steven P. Rowe, Sarah M. Schwarzenboeck, Stefano Fanti, Ken Herrmann
Summary: The development of consensus guidelines for interpretation of PSMA-PET aims to provide consistent clinical reports, increase data reproducibility in clinical trials, and assist clinicians in making treatment decisions. An expert panel actively participated in a modified Delphi consensus process to implement structured reporting for PSMA-PET. The E-PSMA standardized reporting guidelines supported by the European Association of Nuclear Medicine offer consensus statements among experts in PSMA-PET imaging to harmonize diagnostic interpretation criteria.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Medicine, General & Internal
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian D. Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie K. Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun A. Azad, Shakher Ramdave, Andrew D. Redfern, William Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y. Zhang, Margaret M. McJannett, Martin R. Stockler, John A. Violet, Scott G. Williams, Andrew J. Martin, Ian D. Davis
Summary: [Lu-177]Lu-PSMA-617 showed a higher PSA response and fewer grade 3-4 adverse events compared to cabazitaxel in men with metastatic castration-resistant prostate cancer.
Review
Oncology
Dominic Bagguley, Sean Ong, James P. Buteau, Sam Koschel, Nattakorn Dhiantravan, Michael S. Hofman, Louise Emmett, Declan G. Murphy, Nathan Lawrentschuk
Summary: PSMA PET/CT is a novel imaging technique for detection and staging of prostate cancer, with recent high-quality prospective studies showing promising results. However, incorporation into clinical guidelines and practice remains limited.
Review
Radiology, Nuclear Medicine & Medical Imaging
Courtney Lawhn-Heath, Ali Salavati, Spencer C. Behr, Steven P. Rowe, Jeremie Calais, Wolfgang P. Fendler, Mattias Eiber, Louise Emmett, Michael S. Hofman, Thomas A. Hope
Summary: PSMA-targeted radiopharmaceuticals play a significant role in diagnosing and treating prostate cancer, with higher detection rates compared to conventional imaging and potential to change management plans, contributing positively to the advancement of prostate cancer imaging.
Article
Endocrinology & Metabolism
Ayanthi Wijewardene, Jeremy Hoang, Aung Min Maw, Matti Gild, Lyndal Tacon, Paul Roach, Geoffrey Schembri, David Chan, Roderick Clifton-Bligh
Summary: In this study, a new scoring system (I-PET) combining whole body scan (WBS) and FDG findings was proposed to identify patients who are refractory to radioactive iodine in thyroid cancer. The results showed that patients with I-PET [3B] were more likely to receive multikinase inhibitor therapy and had a higher mortality rate.
CLINICAL ENDOCRINOLOGY
(2023)
Article
Oncology
Megan Crumbaker, Sarennya Pathmanandavel, Andrew O. Yam, Andrew Nguyen, Bao Ho, Lyn Chan, Jesse A. Ende, Christopher Rofe, Kamonwan Kongrak, Edmond M. Kwan, Arun A. Azad, Shikha Sharma, Trevor J. Pugh, Arnavaz Danesh, Joanne Keane, Peter Eu, Anthony M. Joshua, Louise Emmett
Summary: Combination therapy of NOX66 with LuPSMA-617 is safe and feasible in men with mCRPC who have received third-line therapy and beyond. Further research is needed to explore the potential of this combination therapy in enhancing the anticancer effects of LuPSMA-617.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Article
Oncology
Wei Liu, Katherine Zukotynski, Louise Emmett, Hans T. Chung, Peter Chung, Robert Wolfson, Irina Rachinsky, Anil Kapoor, Ur Metser, Andrew Loblaw, Gerard Morton, Tracy Sexton, Michael Lock, Joelle Helou, Alejandro Berlin, Colm Boylan, Susan Archer, Gregory R. Pond, Glenn Bauman
Summary: The study aimed to investigate the effect of adding PSMA-targeted PET/CT in patients with recurrent prostate cancer post-primary radiation therapy. Most patients had a major change in actual management compared with pre-PET/CT planned management.
ADVANCES IN RADIATION ONCOLOGY
(2021)
